Dermata Therapeutics, Inc.
DRMA
$1.27
$0.010.79%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 36.32% | 52.41% | 32.05% | -33.95% | -7.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -40.62% | -45.42% | -38.53% | -26.96% | 44.17% |
| Operating Income | 40.62% | 45.42% | 38.53% | 26.96% | -44.17% |
| Income Before Tax | 40.91% | 46.68% | 39.87% | 26.50% | -47.65% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 40.91% | 46.68% | 39.87% | 26.50% | -47.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 40.91% | 46.68% | 39.87% | 26.50% | -47.65% |
| EBIT | 40.62% | 45.42% | 38.53% | 26.96% | -44.17% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 82.04% | 91.92% | 93.62% | 93.67% | 86.27% |
| Normalized Basic EPS | 82.04% | 91.92% | 93.62% | 93.67% | 86.27% |
| EPS Diluted | 82.04% | 91.92% | 93.62% | 93.67% | 86.27% |
| Normalized Diluted EPS | 82.04% | 91.92% | 93.62% | 93.67% | 86.27% |
| Average Basic Shares Outstanding | 228.98% | 560.13% | 842.10% | 1,061.04% | 974.06% |
| Average Diluted Shares Outstanding | 228.98% | 560.13% | 842.10% | 1,061.04% | 974.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |